Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Published August 9, 2010
Citation Information: J Clin Invest. 2010;120(9):3310-3325. https://doi.org/10.1172/JCI42391.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 15

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice

  • Text
  • PDF
Abstract

Some cancers have been stratified into subclasses based on their unique involvement of specific signaling pathways. The mapping of human cancer genomes is revealing a vast number of somatic alterations; however, the identification of clinically relevant molecular tumor subclasses and their respective driver genes presents challenges. This information is key to developing more targeted and personalized cancer therapies. Here, we generate a new mouse model of genomically unstable osteosarcoma (OSA) that phenocopies the human disease. Integrative oncogenomics pinpointed cAMP-dependent protein kinase type I, α regulatory subunit (Prkar1a) gene deletions at 11qE1 as a recurrent genetic trait for a molecularly distinct subclass of mouse OSA featuring RANKL overexpression. Using mouse genetics, we established that Prkar1a is a bone tumor suppressor gene capable of directing subclass development and driving RANKL overexpression during OSA tumorigenesis. Finally, we uncovered evidence for a PRKAR1A-low subset of human OSA with distinct clinical behavior. Thus, tumor subclasses develop in mice and can potentially provide information toward the molecular stratification of human cancers.

Authors

Sam D. Molyneux, Marco A. Di Grappa, Alexander G. Beristain, Trevor D. McKee, Daniel H. Wai, Jana Paderova, Meenakshi Kashyap, Pingzhao Hu, Tamara Maiuri, Swami R. Narala, Vuk Stambolic, Jeremy Squire, Josef Penninger, Otto Sanchez, Timothy J. Triche, Geoffrey A. Wood, Lawrence S. Kirschner, Rama Khokha

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2016 2015 2014 2013 2012 2011 2010 2009 Total
Citations: 3 2 1 4 3 2 3 9 4 12 4 5 3 1 1 57
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (57)

Title and authors Publication Year
CA9, CYFIP2 and LGALS3BP-A Novel Biomarker Panel to Aid Prognostication in Glioma.
Hudson AL, Cho A, Colvin EK, Hayes SA, Wheeler HR, Howell VM
Cancers 2024
Identification of hub genes related to metastasis and prognosis of osteosarcoma and establishment of a prognostic model with bioinformatic methods
Fu Z, Sun G, Li J, Yu H
Medicine 2024
Injectable hyaluronate-L- cysteine gel potentiates photothermal therapy in osteosarcoma via vorinostat-copper cell death
Wang S, Zhang H, Chen T, Jiang W, Wang F, Yu Y, Guo B, Xu J, Yang F, Kang Q, Ma Z
Materials Today Bio 2024
Cellular dynamics of distinct skeletal cells and the development of osteosarcoma
Otani S, Ohnuma M, Ito K, Matsushita Y
Frontiers in Endocrinology 2023
The generation and use of animal models of osteosarcoma in cancer research
Pu F, Guo H, Shi D, Chen F, Peng Y, Huang X, Liu J, Zhang Z, Shao Z
Genes & Diseases 2023
Elevated Protein Kinase A Activity in Stomach Mesenchyme Disrupts Mesenchymal-epithelial Crosstalk and Induces Preneoplasia.
Puri P, Grimmett G, Faraj R, Gibson L, Gilbreath E, Yoder BK
Cellular and Molecular Gastroenterology and Hepatology 2022
Osteosarcoma and Metastasis Associated Bone Degradation—A Tale of Osteoclast and Malignant Cell Cooperativity
KS Nørregaard, HJ Jürgensen, H Gårdsvoll, LH Engelholm, N Behrendt, K Søe
International journal of molecular sciences 2021
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma
HM Torres, AM VanCleave, M Vollmer, DL Callahan, A Smithback, JM Conn, T Rodezno-Antunes, Z Gao, Y Cao, Y Afeworki, J Tao
Cancers 2021
Preclinical In Vivo Modeling of Pediatric Sarcoma—Promises and Limitations
R Imle, FK Kommoss, A Banito
Journal of Clinical Medicine 2021
Research models and mesenchymal/epithelial plasticity of osteosarcoma
X Yu, JT Yustein, J Xu
Cell & Bioscience 2021
Targeting Mechanotransduction in Osteosarcoma: A Comparative Oncology Perspective
AK Luu, AM Viloria-Petit
International journal of molecular sciences 2020
Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma
LJ Mills, MC Scott, P Shah, AR Cunanan, A Deshpande, B Auch, B Curtin, KB Beckman, LG Spector, AL Sarver, S Subramanian, TA Richmond, JF Modiano
Bone 2020
PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A
S Espiard, L Drougat, N Settas, S Haydar, K Bathon, E London, I Levy, F Faucz, D Calebiro, J Bertherat, D Li, M Levine, C Stratakis
Endocrine Related Cancer 2020
PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells
, Z Qi, J Ma, Y Chen
Clinical & Experimental Metastasis 2019
Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond
MV Deligiorgi, MI Panayiotidis, J Griniatsos, DT Trafalis
Clinical & Experimental Metastasis 2019
Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53
MK Walia, S Taylor, PW Ho, TJ Martin, CR Walkley
Cell Death and Disease 2018
Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations
C Jacques, N Renema, F Lezot, B Ory, CR Walkley, AE Grigoriadis, D Heymann
Journal of Bone Oncology 2018
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
AJ Saraf, JM Fenger, RD Roberts
Frontiers in Oncology 2018
Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance: ( A ) Heat map of qPCR data. Expression of the PTHrP/CREB1 and p53 target genes between indicated cell types. Data from >3 independent cell lines for each, expressed as fold change relative to non-tamoxifen treated isogenic culture. ( B ) Western blot of p53, pCREB1 and CREB1, β -ACTIN used as a loading control. Data representative of 2–3 independent cell lines from each. ( C ) Quantification of cAMP levels (+IBMX) in the R26 -CreER T2 p53 +/+ (vehicle and tamoxifen treated) and R26 -CreER T2 p53 fl/fl vehicle and tamoxifen treated (p53△/△) primary osteoblasts, and day 5, 10, 15 and 20 days post tamoxifen. Data from 2 R26 -CreER T2 p53 +/+ and 4 R26 -CreER T2 p53 fl/fl independent cultures; mean ± SEM. ( D ) Experimental outline for proliferation assay; Western blot of p53, pCREB1 and CREB1 in indicated cell types, β -ACTIN used as a loading control at Day 0 of culture. Proliferation assays performed in the indicated genotype post CREB1 ( E ) and PTHrP ( F ) knockdown with tamoxifen treatment commencing at day 0; shLuc = control shRNA; Data from 4 independent R26 -CreER T2 p53 fl/fl and 2 R26 -CreER T2 p53 +/+ cultures; mean ± SEM and statistics = area under the curve across the time course. ( G ) AnnexinV/7-AAD profiles of R26 -CreER T2 p53 fl/fl +/- tamoxifen treatment infected with control (shLuc), sh Creb1 _A or sh Pthlh _A. ( H ) Percent apoptotic cells in each culture +/- tamoxifen. ( I ) Heat map of qPCR data. Expression of the p53 and PTHrP/CREB1 target genes between cell types; 3 independent cell cultures for each condition. Data expressed as mean ± SEM (n=3). For all panels: *pFigure 1—figure supplement 1 and Figure 1—figure supplement 2
MK Walia, PM Ho, S Taylor, AJ Ng, A Gupte, AM Chalk, AC Zannettino, TJ Martin, CR Walkley
eLife 2016
Molecular genetics of osteosarcoma
K Rickel, F Fang, J Tao
Bone 2016
Deciphering signaling networks in osteosarcoma pathobiology
C Adamopoulos, AN Gargalionis, EK Basdra, AG Papavassiliou
Experimental biology and medicine (Maywood, N.J.) 2016
Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects
E Saloustros, S Liu, EL Mertz, N Bhattacharyya, MF Starost, P Salpea, M Nesterova, M Collins, S Leikin, CA Stratakis
Molecular and Cellular Endocrinology 2016
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies
A Abarrategi, J Tornin, L Martinez-Cruzado, A Hamilton, E Martinez-Campos, JP Rodrigo, MV González, N Baldini, J Garcia-Castro, R Rodriguez
Stem Cells International 2016
Fatty acid extract from CLA-enriched egg yolks can mediate transcriptome reprogramming of MCF-7 cancer cells to prevent their growth and proliferation
AA Koronowicz, P Banks, D Domagała, A Master, T Leszczyńska, E Piasna, M Marynowska, P Laidler
Genes & Nutrition 2016
PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma
S Wang, Y Cheng, Y Zheng, Z He, W Chen, W Zhou, C Duan, C Zhang
Scientific Reports 2016
Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis
E Saloustros, P Salpea, M Starost, S Liu, FR Faucz, E London, E Szarek, WJ Song, M Hussain, CA Stratakis
Endocrine Related Cancer 2016
RANKL inhibitors for osteosarcoma treatment: hope and caution
EM Trinidad, E González-Suárez
Annals of translational medicine 2016
Preclinical mouse models of osteosarcoma
Ö Uluçkan, A Segaliny, S Botter, JM Santiago, AJ Mutsaers
BoneKEy Reports 2015
RANK and RANK ligand expression in primary Human osteosarcoma
D Branstetter, K Rohrbach, LY Huang, R Soriano, M Tometsko, M Blake, AP Jacob, WC Dougall
Journal of Bone Oncology 2015
Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population
K Wang, J Zhao, M He, M Fowdur, T Jiang, S Luo
Tumor Biology 2015
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies
Morrow JJ, Khanna C
Critical Reviews in Oncogenesis 2015
Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo
PW Ho, A Goradia, MR Russell, AM Chalk, KM Milley, EK Baker, JA Danks, JL Slavin, M Walia, B Crimeen-Irwin, RA Dickins, TJ Martin, CR Walkley
Oncogene 2014
Notch Activation as a Driver of Osteogenic Sarcoma
J Tao, MM Jiang, L Jiang, JS Salvo, HC Zeng, B Dawson, TK Bertin, PH Rao, R Chen, LA Donehower, F Gannon, BH Lee
Cancer Cell 2014
Translational biology of osteosarcoma
M Kansara, MW Teng, MJ Smyth, DM Thomas
Nature Reviews Cancer 2014
PKA signaling drives mammary tumorigenesis through Src
AG Beristain, SD Molyneux, PA Joshi, NC Pomroy, MA di Grappa, MC Chang, LS Kirschner, GG Privé, MA Pujana, R Khokha
Oncogene 2014
High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma
W Yang, H Maolin, Z Jinmin, W Zhe
Journal of Cancer Research and Clinical Oncology 2014
Loss of Prkar1a leads to Bcl-2 family protein induction and cachexia in mice
L Gangoda, M Doerflinger, R Srivastava, N Narayan, LE Edgington, J Orian, C Hawkins, LA O'Reilly, H Gu, M Bogyo, P Ekert, A Strasser, H Puthalakath
Cell Death and Differentiation 2014
Animal Models in Osteosarcoma
MV Guijarro, SC Ghivizzani, CP Gibbs
Frontiers in Oncology 2014
SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization
BK Seong, J Lau, T Adderley, L Kee, D Chaukos, M Pienkowska, D Malkin, P Thorner, MS Irwin
Oncogene 2014
PTHrP, its receptor, and protein kinase A activation in osteosarcoma
CR Walkley, MK Walia, PW Ho, TJ Martin
Molecular & Cellular Oncology 2014
The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse
T Quist, H Jin, JF Zhu, K Smith-Fry, MR Capecchi, KB Jones
Oncogene 2014
Knockdown of PRKAR1A , the Gene Responsible for Carney Complex, Interferes With Differentiation in Osteoblastic Cells
M Zhang, PK Manchanda, D Wu, Q Wang, LS Kirschner
Molecular Endocrinology 2014
GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population
Jiang C, Chen H, Shao L, Dong Y
Medical Oncology 2014
Localized interleukin-12 delivery for immunotherapy of solid tumours
LZ Wei, Y Xu, ME Nelles, C Furlonger, JC Wang, MA di Grappa, R Khokha, JA Medin, CJ Paige
Journal of Cellular and Molecular Medicine 2013
Genome-wide association study identifies two susceptibility loci for osteosarcoma
SA Savage, L Mirabello, Z Wang, JM Gastier-Foster, R Gorlick, C Khanna, AM Flanagan, R Tirabosco, IL Andrulis, JS Wunder, N Gokgoz, A Patiño-Garcia, L Sierrasesúmaga, F Lecanda, N Kurucu, IE Ilhan, N Sari, M Serra, C Hattinger, P Picci, LG Spector, DA Barkauskas, N Marina, SR de Toledo, AS Petrilli, MF Amary, D Halai, DM Thomas, C Douglass, PS Meltzer, K Jacobs, CC Chung, SI Berndt, MP Purdue, NE Caporaso, M Tucker, N Rothman, MT Landi, DT Silverman, P Kraft, DJ Hunter, N Malats, M Kogevinas, S Wacholder, R Troisi, L Helman, JF Fraumeni, M Yeager, RN Hoover, SJ Chanock
Nature Genetics 2013
cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse
CA Stratakis
Molecular and Cellular Endocrinology 2013
Phylooncogenomics: Examining the cancer genome in the context of vertebrate evolution
GJ Zhang, TH Vemulapalli, JY Yang
Applied & Translational Genomics 2013
Denosumab treatment for fibrous dysplasia
AM Boyce, WH Chong, J Yao, RI Gafni, MH Kelly, CE Chamberlain, C Bassim, N Cherman, M Ellsworth, JZ Kasa-Vubu, FA Farley, AA Molinolo, N Bhattacharyya, MT Collins
Journal of Bone and Mineral Research 2012
Genetically engineered mouse models and human osteosarcoma
AJ Ng, AJ Mutsaers, EK Baker, CR Walkley
Clinical Sarcoma Research 2012
Cre transgene results in global attenuation of the cAMP/PKA pathway
L Gangoda, M Doerflinger, YY Lee, A Rahimi, N Etemadi, D Chau, L Milla, L O'Connor, H Puthalakath
Cell Death and Disease 2012
Children's Oncology Group's 2013 blueprint for research: Bone tumors
R Gorlick, K Janeway, S Lessnick, RL Randall, N Marina
Pediatric Blood & Cancer 2012
QUANTIFYING NANOPARTICLE TRANSPORT IN VIVO USING HYPERSPECTRAL IMAGING WITH A DORSAL SKINFOLD WINDOW CHAMBER
TD Mckee, J Chen, I Corbin, G Zheng, R Khokha
Journal of Innovative Optical Health Sciences 2012
Osteosarcomagenesis: Modeling Cancer Initiation in the Mouse
KB Jones
Sarcoma 2011
How does cAMP/Protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
MQ Almeida, CA Stratakis
Molecular and Cellular Endocrinology 2011
The transcriptome that mediates increased cyclic adenosine monophosphate signaling in PRKAR1A defects and other settings
MF Azevedo, CA Stratakis
Endocrine Practice 2011
Protein kinase A regulates caspase-1 via Ets-1 in bone stromal cell-derived lesions: a link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors
MQ Almeida, KM Tsang, C Cheadle, T Watkins, JC Grivel, M Nesterova, R Goldbach-Mansky, CA Stratakis
Human Molecular Genetics 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Referenced in 3 patents
On 1 Facebook pages
56 readers on Mendeley
1 readers on CiteULike
See more details